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and  symptom  directed  [1].  Symptomatic,  persistent  AF  can  be  unrelenting  and  result  in  a
signiﬁcant  reduction  in  the  patient’s  quality  of  life.  To  alleviate  these  symptoms,  besides
provision  of  adequate  rate-limiting  agents,  clinicians  may  alternatively  offer  rhythm  con-
trol,  for  example,  cardioversion  to  bring  about  restoration  of  sinus  rhythm.  Nevertheless,
the  risk  of  peri-cardioversion  thromboembolism  is  high.
Thus,  guidelines  demand  for  utilisation  of  oral  anticoagulation,  traditionally  Vitamin
K  antagonist  (VKA,  eg.  warfarin)  with  a  minimum  of  therapeutic  anticoagulation  (INR
2.0—3.0)  for  3  weeks  pre-cardioversion  then  for  a  minimum  of  4  weeks  post-cardioversion,
but  continued  longer  term  where  stroke  risk  factors  are  evident  [2].  The  use  of  transoe-
sophageal  echocardiography  can  potentially  avoid  pre-cardioversion  anticoagulation  and
expedite  cardioversion  by  excluding  atrial  thrombus,  but  the  need  for  post-cardioversion
anticoagulation  still  remains.
Until  recently,  VKAs  and  unfractionated  heparin  (UFH)  were  the  only  available  anti-
coagulants,  but  their  use  was  hampered  by  the  need  of  close  monitoring  and  adherence
to  a  tight  therapeutic  range  (be  it  international  normalised  ratio,  INR,  or  activated  par-
tial  thromboplasmin  time,  aPTT)  [3,4].  With  VKAs,  there  is  also  the  recognition  that  good
quality  anticoagulation  control  (as  reﬂected  by  the  time  in  therapeutic  range  (TTR)  is  nec-
essary,  to  minimise  the  risks  of  thromboembolism  and  bleeding  [5].  Fondaparinux,  on  the
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ther  hand,  is  an  indirect  Factor  Xa  inhibitor,  that  is  effec-
ive  in  treatment  for  both  venous  thrombosis  and  acute
oronary  syndrome  [6,7].  Thus,  the  question  remains:  is  fon-
aparinux  an  effective  anticoagulant  in  patients  with  AF?
In  this  issue  of  Archives  of  Cardiovascular  Diseases,
ohen  et  al.  investigate  the  use  of  fondaparinux  in  the
etting  of  electrical  cardioversion  of  AF.  The  safety  of
ondaparinux  in  transoesophageal  echocardiography-guided
lectric  cardioversion  of  atrial  ﬁbrillation  (SAFE-AF)  study
as  an  international  phase  II  pilot  study,  involving  349
atients  with  AF  who  were  scheduled  to  undergo  electric
ardioversion  [8].  During  the  course  of  the  study,  tran-
oesophageal  echocardiogram  was  used  to  establish  the
bsence  of  thrombus  in  left  atrium  or  corresponding  atrial
ppendage,  prior  to  randomisation  to  fondaparinux  or  VKA
plus  UFH)  arm.  Subsequent  electric  cardioversion  was  done,
ith  post-procedural  anticoagulation  for  4  weeks  and  out-
atient  follow-up  period  of  up  to  90  days.
The  chief  purpose  of  this  phase  II  trial  was  to  establish
he  safety  of  use  of  fondaparinux  in  AF  patients  undergo-
ng  cardioversion,  thus  the  primary  endpoint  of  combined
ate  of  ischaemic  stroke,  thromboembolism,  bleeding  events
nd  death  during  treatment  phase  is  of  particular  interest.
his  study  demonstrated  relatively  higher  primary  endpoint
vent  rate  (1.7%  versus  1.2%)  with  fondaparinux  compared
o  VKA.  Bleeding  rates  were  also  higher  with  fondaparinux
ompared  to  VKA,  1.7%  versus  0.6%.
When  compared  to  a  previous  study,  the  Anticoagulation
n  Cardioversion  Enoxaparin  (ACE)  trial  [9],  the  absolute
ate  of  combined  safety  and  efﬁcacy  event  rate  in  fonda-
arinux  was  signiﬁcantly  lower  (2.8%  enoxaparin  and  4.8%
KA),  together  with  more  modest  major  bleeding  rate  (0.8%
noxaparin  and  2.4%  VKA).  Nevertheless,  with  such  a  small
ample  size  in  each  treatment  arm  and  without  more  data
rom  the  VKA  group,  such  as  the  TTR,  it  is  difﬁcult  to  estab-
ish  if  the  seemingly  higher  primary  endpoint  and  bleeding
ate  in  the  fondaparinux  group  was  due  to  chance  or  as
 reﬂection  of  better  oral  anticoagulation  control  in  VKA
roup.
These  results  should  put  in  context  with  the  recently
ublished  eXplore  the  efﬁcacy  and  safety  of  once-daily  oral
iVaroxaban  for  the  prevention  of  cardiovascular  events  in
atients  with  non-valvular  atrial  ﬁbrillation  scheduled  for
ardioversion  (X-VeRT)  study  [10].  X-VeRT  compared  VKA
ith  rivaroxaban,  a  selective  factor  Xa  antagonist,  and  the
rimary  composite  endpoint  rate  (including  stroke,  systemic
hromboembolism,  myocardial  infarction  and  death)  was
.51%  with  rivaroxaban  versus  1.02%  with  VKA,  with  a  safety
ndpoint  rate  (fatal  and  major  bleeds)  of  0.61%  versus  0.80%
or  rivaroxaban  compared  to  VKA,  respectively.  Other  reas-
uring  data  for  the  non-VKA  oral  anticoagulants  (NOACs)
ome  from  post-hoc  analyses  of  their  phase  3  trials,  showing
imilar  efﬁcacy  and  safety  of  dabigatran  and  apixaban  com-
ared  to  warfarin,  when  used  peri-cardioversion  [11,12].
Hence,  although  the  SAFE-AF  study  was  novel,  it  was
mall  and  underpowered.  However,  it  did  suggest  that  fonda-
arinux  use  in  AF  was  associated  with  a  low  rate  of  systemic
hromboembolism  in  return  for  a  modest  major  bleeding
isk,  as  compared  to  the  combined  VKA  and  UFH  treat-
ent.  Nonetheless,  the  performance  of  fondaparinux  pales
n  comparison  to  more  contemporary  oral  anticoagulants,  as
emonstrated  in  the  X-VeRT  study.Y.C.  Lau  et  al.
Second,  amongst  those  patients  whom  thrombus  had
een  discovered,  4  weeks  of  mandatory  anticoagulation  use
as  given  to  allow  for  dissolution  of  thrombus.  Indeed,
he  sustained  use  of  fondaparinux  brought  about  a  higher
roportion  of  thrombus  clearance  as  compared  to  VKA
78.6%  versus  50%),  although  not  statistically  signiﬁcant
P  =  0.24).  Conversely,  some  anecdotal  case  reports  [13,14]
ave  even  suggested  that  off-label  treatment  with  fon-
aparinux  may  bring  about  formation  of  atrial  thrombus.
herefore,  although  the  use  of  fondaparinux  to  promote
eft  atrial  thrombus  dissolution  may  appear  plausible,  one
hould  still  practise  caution  when  using  it  as  an  alternative
nticoagulant  over  VKA  or  UFH.
Third,  when  comparing  fondaparinux  with  VKA,  the  use  of
ondaparinux  had  a  shorter  mean  duration  of  hospital  stay,
.9  days  versus  8.1  days.  This  perhaps  reﬂects  the  pharma-
okinetics  and  dynamics  of  VKA,  and  the  time  taken  for  INR
o  reach  therapeutic  range  (especially  since  this  would  be
nﬂuenced  by  many  clinical  risk  factors  [15])  and  could  have
robably  resulted  in  prolongation  of  inpatient  stay  among
KA  users.
In  conclusion,  the  SAFE-AF  study  has  established  the
dea  that  an  injectable,  indirect  factor  Xa  inhibitor
fondaparinux)  may  potentially  be  a safe  and  effective
nticoagulant  in  AF  patients  prior  to  cardioversion.  The
nce-daily  injection  is  deﬁnitely  an  attractive  option  over
wice  daily  low-molecular  weight  heparin  or  continuous
FH  infusion.  Nevertheless,  with  the  advent  of  plethora  of
OACs,  the  role  of  injectable  anticoagulants  has  diminished.
his  is  further  exacerbated  by  the  lack  of  robust  data  from
arge  prospective  randomised  controlled  trials.
With  the  recent  publication  of  the  X-VeRT  study  (relat-
ng  to  rivaroxaban),  other  open-labelled  trials  involving
OACs  in  the  peri-cardioversion  period  are  ongoing,  for
xample,  the  EMANATE  trial  (with  apixaban)  and  ENSURE-
F  (with  edoxaban).  These  trials  may  potentially  reinforce
he  preponderance  of  NOAC  use  over  VKA  or  injectable  anti-
oagulants.  For  now,  NOACs  have  certainly  streamlined  the
pproach  to  anticoagulation  for  AF  cardioversion,  and  by
voiding  the  delays  with  VKAs  to  achieve  therapeutic  anti-
oagulation,  they  are  therefore  here  to  stay.
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